Hutchison China MediTech Ltd. (HCM)
| Market Cap | 4.87B |
| Revenue (ttm) | 204.89M |
| Net Income (ttm) | -106.02M |
| Shares Out | 665.68M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $33.82 |
| Previous Close | $35.00 |
| Change ($) | -1.18 |
| Change (%) | -3.37% |
| Day's Open | 35.03 |
| Day's Range | 33.50 - 35.33 |
| Day's Volume | 172,015 |
| 52-Week Range | 15.19 - 36.80 |
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“I...
– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China –
– Company plans to complete rolling submission in the first half of 2021 –
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chie...
Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of ...
― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that its New Drug Appli...
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III reg...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HM...
HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the stud...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it received scientific ...
Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib –
HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products ...
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today anno...
— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
LONDON, June 18, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast...
LONDON, June 09, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Compan...
LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIG...
LONDON, June 01, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with ...
— First NDA filing of savolitinib globally —
LONDON, April 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two...
LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor tar...
Hutchison China MediTech (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Hutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q4 2019 Results - Earnings Call Transcript
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Hutchison China MediTech Limited (HCM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
As of late, it has definitely been a great time to be an investor in Hutchison China MediTech.
LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase ...
Does Hutchison China MediTech (HCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (t...
LONDON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38t...
LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medic...
Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China
LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted ...
LONDON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orph...
LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treat...
LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted ag...
SUZHOU, China and LONDON, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today annou...
LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyros...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Hutchison China MediTech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
– Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study –
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented –
LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fr...
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a ...
About HCM
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunsh... [Read more...]
| Industry Biotechnology | |
| CEO Christian Hogg | Employees 853 |
| Stock Exchange NASDAQ | Ticker Symbol HCM |
Financial Performance
In 2019, HCM's revenue was $204.89 million, a decrease of -4.31% compared to the previous year's $214.11 million. Losses were -$106.02 million, 41.7% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for HCM stock is "Strong Buy." The 12-month stock price forecast is 38.72, which is an increase of 14.49% from the latest price.